Attana has filed an international patent application with claims for methods for assessing the neutralizing potential of antibodies in biological samples. The application claims priority from the national application filed February 18, 2022 and designates all PCT contracting states. The invention is applicable in both of Attana's business areas - Life Science and Diagnostics.

The patent application contains several claims assessing the neutralizing potential of antibodies or other biological entities in complex biological samples. The invention can be applied within diagnostics with the purpose to better determine the immunity of individuals based on several parameters, such as kinetics and titers of immune responding agents. Additionally, it can also be applied in both pre-clinical and clinical drug development to obtain increased information on human immune response, e.g. antibody-drug antibodies.

The Attana patent application covers several aspects on assessing kinetics of an interaction between e.g, an antigen and an antibody as well as the combination with neutralizing titer. The work has been performed in collaboration with Prof. Ian Nicholls and Dr. Per Nilsson at the Linnaeus University.